SpineGuard and Omnia Medical received notice of allowance from the United States Patent and Trademark Office (USPTO) for their application of DSG technology to sacroiliac joint fusion.
The recently allowed patent applications by the USPTO, applied jointly by SpineGuard and Omnia Medical, describe the utilization of the DSG tissue differentiating feedback technology for the precise positioning of sacroiliac fusion implants.
The sterile-delivered surgical kit that includes Omnia’s implants, instruments, biologics, as well as SpineGuard’s PsiFGuard guidance tool, is suitable for light operative setups such as ambulatory centers or offices. The commercial launch acceleration of the product combination in the U.S., with its now fully protected surgical technique, is a key step of the common roadmap announced by both companies early 2025.
SpineGuard and Omnia Medical received notice of allowance from the United States Patent and Trademark Office (USPTO) for their application of DSG technology to sacroiliac joint fusion.
The recently allowed patent applications by the USPTO, applied jointly by SpineGuard and Omnia Medical, describe the utilization of the DSG tissue...
SpineGuard and Omnia Medical received notice of allowance from the United States Patent and Trademark Office (USPTO) for their application of DSG technology to sacroiliac joint fusion.
The recently allowed patent applications by the USPTO, applied jointly by SpineGuard and Omnia Medical, describe the utilization of the DSG tissue differentiating feedback technology for the precise positioning of sacroiliac fusion implants.
The sterile-delivered surgical kit that includes Omnia’s implants, instruments, biologics, as well as SpineGuard’s PsiFGuard guidance tool, is suitable for light operative setups such as ambulatory centers or offices. The commercial launch acceleration of the product combination in the U.S., with its now fully protected surgical technique, is a key step of the common roadmap announced by both companies early 2025.
Copy to clipboard 
